News | May 10, 2021
Cipla signs agreement with Lilly to expand access to COVID-19 treatment in India
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices
Acquisition of A&C expands Aceto’s Western manufacturing footprint
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
Has signed a 12-year, off-site, virtual power purchase agreement (VPPA) with Enel Green Power
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Subscribe To Our Newsletter & Stay Updated
